August 2012
-
OptiNose has announced positive results from the NAVIGATE I Phase 3 trial of its OPN-375 intranasal fluticasone for the treatment of nasal polyposis demonstrating statistically significant reduction of symptoms and total polyp grade. In June… Read more . . .
-
Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor “to assist in exploring strategic options to enhance stockholder value,” the company said. Options being explored include selling corporate assets, a strategic business combination, or… Read more . . .
-
Insys Therapeutics has announced that it will partner with Senzer Ltd, a subsidiary of Kind Consumer, to develop inhaled dronabinol (THC) and cannabidiol (CBD) products. Insys has licensed Senzer’s delivery technology, the same technology in… Read more . . .
-
Adapt Pharma announced that the FDA has accepted its filing and granted priority review to its New Drug Application for Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose. Adapt submitted the NDA… Read more . . .
-
GlaxoSmithKline and Theravance have announced plans to file a supplemental Japanese New Drug Application for the Relvar/Breo Ellipta fluticasone furoate/vilanterol DPI for the treatment of COPD in the first quarter of 2016. The Japanese MHLW… Read more . . .
-
Nemera has announced that after investing over 10 million euros, it now has the capacity to manufacture up to 45 million units of the Advancia user-independent nasal spray pump per year. The company, which was… Read more . . .
-
RMIT University, located in Melbourn, Australia, has announced that it will display the Respite surface acoustic wave nebulizer at TechInnovation 2015. According to RMIT, the device can deliver drug at rates of 3 ml/min, with… Read more . . .
-
Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler has now been approved by the FDA for the treatment of asthma in patients 12 years old and older. Spiriva Respimat was approved for the treatment of… Read more . . .
-
Theravance Biopharma and Mylan announced that they have initiated Phase 3 studies for TD-4208 revefenacin inhalation solution for the treatment of COPD. The Phase 3 program includes 2 12-week efficacy studies plus a 12-month safety… Read more . . .
-
AZTherapies announced that it has initiated a Phase 3 study of its ALZT-OP1 DPI for the treatment of early stage Alzheimer’s disease. ALZT-OP1 is a dry powder formulation of cromolyn and ibuprofen that is delivered… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland